“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and stuttering in adults.
Combining computational modeling and machine learning to create novel, uniquely functioning synthetic proteins with applications across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
News
Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., as [...]
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform Its vision restoration technology featured in Nature and New England [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), [...]